 |
| Palo Alto firm Lucence, which raised $20 million in series A venture funding back in 2019, has signed exclusive licensing deals with both Waseda University and Singapore's A*STAR institution. It is aiming to commercialize a laser-based microfluidics system capable of identifying circulating tumor cells by as soon as next year. Image: Lucence. |
| © 2024 SPIE Europe |
|
